A Mind Map for Managing Minimal Residual Disease in Acute Myeloid Leukemia

  Abstract: Advances in detecting traces of leukemia that were previously unidentifiable have increasingly led to the incorporation of information about residual disease into clinical decision […]

Emerging Treatments in Acute Myeloid Leukemia: Current Standards and Unmet Challenges

  Abstract: Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in […]

Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype

  Abstract: Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile […]

Identifying Patients With Leukemia Who Are at Risk for Fungal Infections

  H&O  Approximately how many patients with leukemia will develop fungal infections? VB  The risk of fungal infection varies according to several factors, such as the […]

Counterpoints: Should Treatment for CML Continue Indefinitely?

Since the advent of tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has been transformed from a disease that was usually fatal into one in which […]

Common Fungal Infections in Patients With Leukemia

  H&O  What is the mortality associated with fungal infections in patients with leukemia? EW  Acute myeloid leukemia (AML) constitutes the hematologic malignancy with the highest […]

Treatment of Acute Lymphoblastic Leukemia in Older Adults: Now and the Future

  Abstract: Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, […]

The New NCCN Guidelines for the Management of Myelofibrosis

H&O  What is myelofibrosis? RM  Myelofibrosis is a myeloproliferative neoplasm, a type of chronic leukemia. Myelofibrosis can evolve from an antecedent polycythemia vera or essential thrombocythemia, […]

BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia

  Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]

The Evolution of Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Myeloid Leukemia

  Abstract: Survival rates in subsets of pediatric patients who have acute myeloid leukemia (AML) with favorable risk features are now greater than 90%. However, outcomes […]

Considerations in the Frontline Treatment of Chronic Lymphocytic Leukemia

  H&O  When is frontline therapy initiated in chronic lymphocytic leukemia (CLL)? SO  The standard approach to CLL is still watch-and-wait. If patients are asymptomatic and […]

The Evolving Role of Chemoimmunotherapy in Chronic Lymphocytic Leukemia

  H&O  What has been the traditional role of chemoimmunotherapy in patients with CLL? NL Traditionally, chemoimmunotherapy was the standard approach in both the frontline and […]

The Best Frontline Therapy for CML: Imatinib?

H&O  What do we know of imatinib’s efficacy as frontline therapy in chronic myeloid leukemia (CML) patients? GS  Imatinib (Gleevec, Novartis) is the most important drug discovered in recent […]

Erythroleukemia: Clinical Course and Management

The Pure Erythroleukemia: A Case Report and Literature Review Naeem Latif, MD, Elaine Salazar, MD, Rubina Khan, MD, Bruce Villas, MD, Fauzia Rana, MD Department of Hematology/Oncology and Pathology, University of Florida […]